News stories about Ligand Pharmaceuticals (NASDAQ:LGND) have trended somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.5998834890625 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
Several brokerages have recently weighed in on LGND. HC Wainwright set a $169.00 price objective on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a report on Friday. BidaskClub upgraded shares of Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, January 5th. Zacks Investment Research lowered shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Deutsche Bank lowered shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating and set a $105.00 price target on the stock. in a report on Monday, November 20th. Finally, Craig Hallum restated a “buy” rating and issued a $170.00 price target (up previously from $160.00) on shares of Ligand Pharmaceuticals in a report on Wednesday, November 15th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $150.67.
Ligand Pharmaceuticals (LGND) traded down $2.51 during midday trading on Tuesday, reaching $146.39. 188,315 shares of the company traded hands, compared to its average volume of 211,710. Ligand Pharmaceuticals has a 52-week low of $95.08 and a 52-week high of $151.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.97 and a quick ratio of 0.95. The stock has a market capitalization of $3,130.00, a price-to-earnings ratio of 212.16, a price-to-earnings-growth ratio of 1.59 and a beta of 0.91.
Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.69 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.32. Ligand Pharmaceuticals had a net margin of 12.76% and a return on equity of 7.83%. The firm had revenue of $33.38 million for the quarter, compared to analyst estimates of $31.04 million. During the same quarter last year, the firm posted $0.62 earnings per share. Ligand Pharmaceuticals’s revenue for the quarter was up 54.4% compared to the same quarter last year. sell-side analysts anticipate that Ligand Pharmaceuticals will post 3.15 earnings per share for the current fiscal year.
In other Ligand Pharmaceuticals news, Director Stephen L. Sabba sold 925 shares of the stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $137.25, for a total value of $126,956.25. Following the completion of the sale, the director now owns 26,985 shares of the company’s stock, valued at $3,703,691.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John L. Higgins sold 5,269 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $142.53, for a total transaction of $750,990.57. Following the completion of the sale, the chief executive officer now directly owns 143,542 shares of the company’s stock, valued at approximately $20,459,041.26. The disclosure for this sale can be found here. Insiders sold 20,253 shares of company stock valued at $2,884,507 in the last ninety days. 8.30% of the stock is owned by corporate insiders.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/16/ligand-pharmaceuticals-lgnd-earns-media-sentiment-score-of-0-14.html.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.